#United States #Immunotherapy #cancer detection #Foster City, California #ADELA

Adela's Groundbreaking Presentation at ASCO 2025

Adela, Inc. is at the forefront of cancer detection and monitoring technologies, focusing on its proprietary blood test that assesses molecular residual disease (MRD). This year, Adela will present new data at the American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for May 30 to June 3, 2025. The research underscores the company's commitment to improving early detection and outcome predictions in cancer patients undergoing immunotherapy.

In its presentation, Adela will share findings from two significant studies demonstrating the efficacy of its MRD test. This cutting-edge test utilizes genome-wide methylome enrichment technology to detect circulating tumor DNA (ctDNA), providing crucial insights into treatment responses and disease progression. Dr. Lillian Siu, a renowned Medical Oncologist from the Princess Margaret Cancer Centre, highlighted the challenge of distinguishing between true disease progression and pseudoprogression in patients undergoing immunotherapy. This differentiation, she notes, is critical for timely treatment adjustments and improving patient outcomes.

Study Insights

The first study focused on advanced cancer patients who received pembrolizumab, an immunotherapy agent. Blood samples were collected before treatment and prior to the third treatment cycle. The results indicated that a decrease in ctDNA levels correlated with significantly improved progression-free survival (PFS) and overall survival (OS) rates in this cohort. With a hazard ratio (HR) of 0.28 for PFS and 0.42 for OS, these results signal the test's potential as a reliable early indicator of treatment efficacy.

In the second study involving patients with stage III/IV non-small cell lung cancer, researchers assessed blood samples taken at various points after treatment initiation. Those who tested positive for MRD exhibited substantially worse PFS compared to patients with negative tests, demonstrating an HR of 4.8 for negative outcomes. These findings reinforce the potential of Adela's MRD test in directing clinical decisions early in a patient's treatment journey.

Advancements in Cancer Testing

Adela's unique approach of utilizing blood samples, as opposed to traditional tissue biopsies, offers a universal solution, particularly for patients where tumor tissue is not readily available. Dr. Anne-Renee Hartman, Chief Medical Officer at Adela, noted the significance of these studies in the context of providing universally accessible MRD testing capabilities. This innovation not only enhances monitoring but also supports informed treatment strategies across diverse cancer types.

The technology is not only intended for clinical settings but is also available for research purposes, aiming to facilitate biomarker discovery and drug development initiatives. Adela anticipates that this MRD test will be commercially available within the year, particularly for patients undergoing curative treatments for head and neck cancers, independent of HPV status, thus enabling earlier recurrence detection.

Presentation Details at ASCO 2025

During the ASCO Annual Meeting, Adela will feature two key abstract presentations related to its MRD technology:

• - Abstract #8550: Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic assay, by Dr. Tuan Hoang.
• - Abstract #2545: Validation of an optimized tissue-agnostic methylome assay to predict clinical outcomes in patients treated with pembrolizumab, by Dr. Enrique Sanz-Garcia.

These presentations will take place in Hall A, with specific poster boards dedicated to showcasing Adela's latest findings during the meeting.

About Adela

Adela is dedicated to revolutionizing cancer diagnosis and management through innovative technologies that facilitate MRD monitoring. By ensuring that vital testing can be done through blood samples rather than reliant on tumor tissues, the company is poised to make significant strides in cancer treatment personalization and accessibility.

In addition to research endeavours, Adela has attracted investments from notable firms including F-Prime Capital and Labcorp, further solidifying its position in the biotech industry. For more information on Adela and its transformative MRD testing, visit adelabio.com.